好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Validation of a Clinical Scale for Defining RBD Severity in Participants of the North American Prodromal Synucleinopathy (NAPS) Consortium
Sleep
P2 - Poster Session 2 (11:45 AM-12:45 PM)
1-001
The objective of this study is to assess the validity of the REM Sleep Behavior Disorder (RBD) symptom severity scale (RBDSSS) and its correlation to the clinical global impression of severity (CGI-S) in a cohort of participants enrolled in the North American Prodromal Synucleinopathy (NAPS) study.

RBD is a prodromal marker of α-synucleinopathies with no standardized tool for assessing severity in clinical or research practice. Development of a reliable scale is essential to understand risk of phenoconversion, monitor response to treatment and clinical trial design.

Participants and their bedpartners enrolled in the NAPS cohort filled out an 8-item questionnaire (RBDSSS), developed by the International RBD Study Group, assessing frequency and severity of dreams, vocalizations, movements, and injuries associated with RBD, with higher scores indicating more severe symptoms. The CGI-S is a 7-point scale ranging from normal (1) to most severely ill (7) and was completed by a clinician based on an independent interview with the participant ± their bedpartners. Data were included when both patient (RBDSSS-PT) and bedpartner (RBDSSS-BP) responses were available. Total scores were derived by multiplying assigned point values for frequency and severity (for each question) and summing them for individual RBDSSS-PT scores (total possible=54) and RBDSSS-BP scores (total possible=38).

The cohort (n=212) included in this analysis was predominantly male (n=175) with a mean ± SE age of 65.16 ± 1.46 years. The median (interquartile range) for RBDSSS-PT, RBDSSS-BP and CGI-S was 11 (4-17), 8 (4-14.3) and 3 (3-4), respectively. Non-parametric Spearman’s rank correlation coefficients (rs) for each variable pair are as follows: RBDSSS-PT vs. RBDSSS-BP, rs=0.576; RBDSSS-PT vs. CGI-S, rs=0.641; RBDSSS-BP vs. CGI-S, rs=0.463 (P<0.0001). 

A moderate correlation was observed between RBDSSS-PT and RBDSSS-BP, suggesting good construct validity for the scale. CGI-S correlated moderately with RBDSSS-PT and weakly with RBDSSS-BP.
Authors/Disclosures
Andrea O. Busicescu
PRESENTER 		Ms. Busicescu has nothing to disclose.
Parichita Choudhury, MD (Banner Sun Health Research Institute) The institution of Dr. Choudhury has received research support from Lewy Body Dementia Association. The institution of Dr. Choudhury has received research support from Arizona Alzheimer's Consortium.
Joyce K. Lee-Iannotti, MD, FAAN (Barrow's Neurological Institute) Dr. Lee-Iannotti has nothing to disclose.
No disclosure on file
David Shprecher, DO, FAAN (Banner Sun Health Research Institute) Dr. Shprecher has received personal compensation for serving as an employee of Banner Health. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanders+Parks. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medplace. The institution of Dr. Shprecher has received research support from MJFF. The institution of Dr. Shprecher has received research support from Cognition Therapeutics. The institution of Dr. Shprecher has received research support from Biogen. The institution of Dr. Shprecher has received research support from Neuraly. The institution of Dr. Shprecher has received research support from Jazz Pharmaceuticals. The institution of Dr. Shprecher has received research support from Sanofi Aventis. The institution of Dr. Shprecher has received research support from Annovis. The institution of Dr. Shprecher has received research support from Neurocrine. The institution of Dr. Shprecher has received research support from Teva. The institution of Dr. Shprecher has received research support from Nuvelution. The institution of Dr. Shprecher has received research support from EIP Pharma. Dr. Shprecher has received personal compensation in the range of $500-$4,999 for serving as a Speaker with International Parkinson's and MDS. Dr. Shprecher has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with Parkinson's Movement Disorder Alliance.
No disclosure on file
Miranda M. Lim, MD, PhD (VA Portland Health Care System) Dr. Lim has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Cognition. Dr. Lim has stock in Applied Cognition. The institution of Dr. Lim has received research support from NIH. The institution of Dr. Lim has received research support from VA. The institution of Dr. Lim has received research support from Department of Defense. The institution of Dr. Lim has received research support from National Science Foundation. Dr. Lim has received publishing royalties from a publication relating to health care.
John Elliott No disclosure on file
Alon Y. Avidan, MD, MPH, FAAN (David Geffen School of Medicine at UCLA) Dr. Avidan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Avidan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avadel. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Harmony. Dr. Avidan has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Harmony. Dr. Avidan has received publishing royalties from a publication relating to health care.
Daniel Huddleston, MD (Emory University) The institution of Dr. Huddleston has received research support from NIH-NINDS 1K23NS105944-01A1. The institution of Dr. Huddleston has received research support from Michael J. Fox Foundation (MJFF-010556). The institution of Dr. Huddleston has received research support from Lewy Body Dementia Association Research Center of Excellence (Emory). The institution of Dr. Huddleston has received research support from American Parkinson's Disease Association.
No disclosure on file
Michael J. Howell, MD, FAAN The institution of Dr. Howell has received research support from National Institutes of Health. Dr. Howell has received publishing royalties from a publication relating to health care.
Carlos H. Schenck, MD (Minnesota Regional Sleep Disorders Center) Dr. Schenck has received personal compensation for serving as an employee of Physicians' 好色先生al Resource, LLC.. Dr. Schenck has received personal compensation for serving as an employee of Eisai Global Medical Affairs.
Susan Criswell, MD (Washington University) Dr. Criswell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie.
Emmanuel H. During, MD (Stanford) Dr. During has nothing to disclose.
Emmanuel Mignot, MD, PhD (Stanford University) Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. Dr. Mignot has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals, Inc. . Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for EcoR1. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for ApneaCo. Dr. Mignot has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Mignot has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Centessa .
Jennifer S. McLeland (Washington University School of Medicine) Ms. McLeland has nothing to disclose.
Amelie Pelletier (Montreal General Hospital) Ms. Pelletier has nothing to disclose.
Jean-Francois Gagnon (Centre D'etude Du Sommeil) The institution of Jean-Francois Gagnon has received research support from Canadian Institute of Health Research. The institution of Jean-Francois Gagnon has received research support from Canada Research Chair. The institution of Jean-Francois Gagnon has received research support from National Institutes of Health.
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Erik K. St. Louis, MD (Mayo Clinic) The institution of Dr. St. Louis has received research support from NIH. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care.
Aleksandar Videnovic, MD, MSc, FAAN (MGH Neurological Clinical Research Institute) Dr. Videnovic has nothing to disclose.
Yo-El Ju, MD The institution of Dr. Ju has received research support from National Institutes of Health.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Ronald Postuma, MD (Montreal General Hospital) Dr. Postuma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche, Biogen, Takeda, Theranexus, GE, Jazz, Curasen, Paladin, Inception Sciences, Phytopharmics, Vaxxinity, Merck. Dr. Postuma has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen/Partners. The institution of Dr. Postuma has received research support from CIHR, Weston Foundation, Webster Foundation, Roche, MJFF, Parkinson Canada, FRSQ, NIH.